We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$587M
AUM Growth
-$222M
Cap. Flow
-$5.15B
Cap. Flow %
-877.82%
Top 10 Hldgs %
35.65%
Holding
170
New
43
Increased
23
Reduced
46
Closed
45

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.7M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$16.8M
3
BIIB icon
Biogen
BIIB
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$8.46M
5
ORA icon
Ormat Technologies
ORA
+$7.92M

Top Sells

Rank Stock Value
1
ISRL
Isramco Inc
ISRL
+$4.99B
2
MRK icon
Merck
MRK
+$24.8M
3
ABBV icon
AbbVie
ABBV
+$23.3M
4
AGN
Allergan Inc
AGN
+$23M
5
JNJ icon
Johnson & Johnson
JNJ
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 63.04%
2 Technology 5.1%
3 Industrials 3.71%
4 Energy 1.9%
5 Consumer Discretionary 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
126
Akebia Therapeutics
AKBA
$354M
– –
-89,817
Closed -$1.99M
ARCT icon
127
CALL
Arcturus Therapeutics
ARCT
$164M
– –
-8,014
Closed -$866K
ATNM icon
128
Actinium Pharmaceuticals
ATNM
$26.3M
– –
-9,710
Closed -$1.95M
BCLI
129
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-4,222
Closed -$265K
BLRX
130
BioLineRX
BLRX
$12.3M
– –
-322
Closed -$298K
BLUE
131
DELISTED
bluebird bio
BLUE
– –
-4,123
Closed -$1.92M
CL icon
132
Colgate-Palmolive
CL
$73.1B
– –
-40,099
Closed -$2.62M
ENLV icon
133
Enlivex Ltd
ENLV
$35.2M
– –
-250
Closed -$1.09M
GOOG icon
134
Alphabet (Google) Class C
GOOG
$4.36T
– –
-166,937
Closed -$4.85M
INCY icon
135
Incyte
INCY
$24.2B
– –
-61,173
Closed -$3M
IRWD icon
136
Ironwood Pharmaceuticals
IRWD
$696M
– –
-231,875
Closed -$2.52M
JNJ icon
137
Johnson & Johnson
JNJ
$618B
– –
-207,406
Closed -$22.1M
MA icon
138
Mastercard
MA
$506B
– –
-26,000
Closed -$1.92M
MBOT icon
139
Microbot Medical
MBOT
$116M
– –
-300
Closed -$612K
MRK icon
140
Merck
MRK
$322B
– –
-437,571
Closed -$24.8M
SLB icon
141
SLB Ltd
SLB
$73.6B
– –
-28,790
Closed -$2.93M
TJX icon
142
CALL
TJX Companies
TJX
$174B
– –
-100,000
Closed -$2.96M
VFC icon
143
VF Corp
VFC
$5.63B
– –
-50,870
Closed -$3.16M
XLV icon
144
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
– –
-485,500
Closed -$31M
XNTK icon
145
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
– –
-400,000
Closed -$39.4M
YUM icon
146
Yum! Brands
YUM
$42.2B
– –
-55,515
Closed -$2.87M
SMMF
147
DELISTED
Summit Financial Group, Inc.
SMMF
– –
-25,000
Closed -$63K
SGEN
148
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-155,360
Closed -$5.78M
CYTO
149
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-2
Closed -$1.11M
OTIC
150
DELISTED
Otonomy, Inc.
OTIC
– –
-111,085
Closed -$2.67M
3 4 5
6
7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sphera Funds Management held 170 positions worth $587M, down 27% from $809M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $5.15B in Q4 2014, closing 45 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 57% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Gilead Sciences worth $17.9M.

  • Sphera Funds Management's largest Q4 2014 buy was Gilead Sciences: 190,000 shares worth $17.9M.
  • Sphera Funds Management added most to SALIX PHARMACEUTICALS LTD DEL in Q4 2014, an estimated $16.8M increase.
  • Sphera Funds Management's biggest Q4 2014 reduction was Isramco Inc, cutting an estimated $4.99B.
  • Sphera Funds Management fully exited Merck in Q4 2014, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $587M portfolio in Q4 2014.
  • Sphera Funds Management opened 43 new positions and closed 45 in Q4 2014.
  • Sphera Funds Management's portfolio value fell 27% quarter-over-quarter to $587M.

Based on Sphera Funds Management's 13F filing for Q4 2014, filed 12 Feb 2015.